Patents by Inventor Martin Glenn
Martin Glenn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12226450Abstract: Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to ?-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.Type: GrantFiled: July 1, 2022Date of Patent: February 18, 2025Assignees: OP-T LLC, The Regents of the University of Colorado, A Body CorporateInventors: David Hal Wagner, Jr., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20250018012Abstract: Methods and compositions are disclosed for treating and preventing cytokine release syndrome (CRS). acute respiratory distress syndrome (CRS), and alveolar capillary injury (ACI) in a subject.Type: ApplicationFiled: June 18, 2024Publication date: January 16, 2025Inventors: David H. Wagner, JR., Gisela M. Vaitaitis, Charles W. Henry, Martin Glenn Yussman
-
Publication number: 20240374686Abstract: Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to B-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.Type: ApplicationFiled: July 30, 2024Publication date: November 14, 2024Inventors: David Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20240115651Abstract: Methods and materials for treating and preventing autoimmune diseases, in particular, multiple sclerosis (MS) including small peptides are capable of interacting with CD40, thereby altering and/or modulating the ability of CD40 to interact with CD154, which apparently affects inflammation; and/or the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response; and/or the use of such short peptides to prevent or reverse autoimmune disease, and particularly, multiple sclerosis, in individuals; and/or methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells. Additionally, methods and apparatuses to administer the peptide are provided.Type: ApplicationFiled: September 14, 2023Publication date: April 11, 2024Inventors: David Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry, Gisela M. Vaitaitis
-
Patent number: 11793854Abstract: Methods and materials for treating and preventing autoimmune diseases, in particular, multiple sclerosis (MS) including small peptides are capable of interacting with CD40, thereby altering and/or modulating the ability of CD40 to interact with CD154, which apparently affects inflammation; and/or the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response; and/or the use of such short peptides to prevent or reverse autoimmune disease, and particularly, multiple sclerosis, in individuals; and/or methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells. Additionally, methods and apparatuses to administer the peptide are provided.Type: GrantFiled: March 23, 2020Date of Patent: October 24, 2023Assignee: OP-T LLCInventors: David Hal Wagner, Jr., Martin Glenn Yussman, Charles W. Henry, Gisela M. Vaitaitis
-
Patent number: 11744875Abstract: Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to ?-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.Type: GrantFiled: July 13, 2020Date of Patent: September 5, 2023Assignee: OP-T LLCInventors: David Hal Wagner, Jr., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20230101772Abstract: Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to ?-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.Type: ApplicationFiled: July 1, 2022Publication date: March 30, 2023Inventors: David H. Wagner, Jr., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20210008162Abstract: Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to ?-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.Type: ApplicationFiled: July 13, 2020Publication date: January 14, 2021Applicant: OP-T LLCInventors: David Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20200326333Abstract: Methods and cellular markers useful for methods of diagnosing autoimmune disease, including type 1 diabetes (T1D) and disease progression in T1D patients, as well as identifying treatments for and monitoring treatment of patients with T1D. Methods of treating patients having T1D.Type: ApplicationFiled: April 10, 2020Publication date: October 15, 2020Applicant: OP-T LLCInventors: David Hal Wagner, Jr., Martin Glenn Yussman, Charles W. Henry, Gisela M. Vaitaitis
-
Publication number: 20200297795Abstract: Methods and materials for treating and preventing autoimmune diseases, in particular, multiple sclerosis (MS) including small peptides are capable of interacting with CD40, thereby altering and/or modulating the ability of CD40 to interact with CD154, which apparently affects inflammation; and/or the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response; and/or the use of such short peptides to prevent or reverse autoimmune disease, and particularly, multiple sclerosis, in individuals; and/or methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells. Additionally, methods and apparatuses to administer the peptide are provided.Type: ApplicationFiled: March 23, 2020Publication date: September 24, 2020Applicant: OP-T LLCInventors: David Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry, Gisela M. Vaitaitis
-
Publication number: 20200072837Abstract: Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may he a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells). Methods and materials for confirming or ruling out cardiovascular disease, atherosclerosis, and/or coronary artery disease.Type: ApplicationFiled: July 31, 2019Publication date: March 5, 2020Applicant: OP-T LLCInventors: David Hal Wagner, Jr., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20190263888Abstract: Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells). Methods and materials for preventing, modulating, reducing and/or reversing type 2 diabetes and auto-inflammatory disease. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and type 2 diabetes. The use of such peptides in reducing type 2 diabetes, and in particular, the autoimmune inflammatory response that may be a driving factor thereof.Type: ApplicationFiled: January 4, 2019Publication date: August 29, 2019Applicant: OP-T LLCInventors: David Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20190194290Abstract: Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells).Type: ApplicationFiled: November 8, 2018Publication date: June 27, 2019Applicant: OP-T LLCInventors: David Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20190102787Abstract: Systems and method for providing staggered offers to a group of users are discussed herein. The system can receive an offer from a partner, which can include a maximum distribution rate (MDR) or a desired time over which the offer will run. Based on the MDR or the desired time, the group of users can be divided into an appropriate number of subgroups, with each subgroup receiving the offer during their respective time period. The system can enable users to receive, claim and redeem offers via a variety of user equipment (UE). Once claimed, an offer can be placed in an electronic prize wallet stored on the UE. The prize wallet can include offers that have been claimed, as well as details to enable the user to redeem the offer with the respective partner.Type: ApplicationFiled: March 5, 2018Publication date: April 4, 2019Inventors: Ahmad O. Alkabra, Bradley Smith, Martin Glenn
-
Patent number: D890343Type: GrantFiled: March 26, 2019Date of Patent: July 14, 2020Assignee: Covvi LimitedInventors: Edward William Varley, Martin Glenn Wallace
-
Patent number: D930161Type: GrantFiled: February 11, 2020Date of Patent: September 7, 2021Assignee: Covvi LimitedInventors: Edward William Varley, Martin Glenn Wallace